On this page
Back to topOdyssey Therapeutics ODTX
Odyssey Therapeutics listed on Nasdaq on 8 May 2026 and is not in the S&P 500. It is worth $882 million. Its price history starts on 8 May 2026. 11 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 5 other officers are on file. At 30 Jun 2026, Fidelity (FMR) was its largest institutional holder, with 10.8% of the company.
- CEO
- Gary D. Glick
- Listed
- 8 May 2026 on Nasdaq, IPO filings and terms
- Headquarters
- Boston, MA
- Market cap
- $882M
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Financial history
Twelve months to 30 Sep 2025, from Odyssey Therapeutics' quarterly filings.
Quarters since Mar 2025
- P/E
- -
- No profit over the last four quarters
Quarterly results
Each quarter's revenue, net income and free cash flow.
Mar 2025 to Sep 2025
Not reported for enough quarters.
Not reported for enough quarters.
Not reported for enough quarters.
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2025 | $99,000 | $-35M |
| Jun 2025 | $959,000 | $-41M |
| Mar 2025 | $2M | $-38M |
Odyssey Therapeutics' market cap since May 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $920M |
Download Odyssey Therapeutics' data as JSON, with the weekly market caps in billions of dollars from 8 May 2026.
Board and leadership
Board and officers
2 people here also hold roles at other S&P 500 companies.
Roles filed up to 30 Sep 2026
| Name | Title |
|---|---|
| Directors (11) | |
| Gary D. GlickPresident and Chief Executive Officer | |
| Shelley ChuDirector | |
| Paulina HillDirector | |
| Jeffrey M. LeidenDirectorAlso at Vertex Pharmaceuticals | |
| Nan (ln) LiDirector | |
| Carolyn NgDirector | |
| Valerie OdegardDirector | |
| Aranicki Ksenija PavleticDirector | |
| Ian F. SmithDirector | |
| Ourania TatsisDirectorAlso at Vertex Pharmaceuticals | |
| Timothy P. WalbertDirector | |
| Officers (5) | |
| Jason HaasChief Financial OfficerLast filed 11 May 2026 | |
| Natalie DalesChief of Research Operations and Portfolio StrategyLast filed 11 May 2026 | |
| Anthony W. OpipariInterim Chief Medical Officer and Executive Vice President, Translational MedicineLast filed 11 May 2026 | |
| Jolie SiegelExecutive Vice President, General Counsel and SecretaryLast filed 7 May 2026 | |
| Collin M. ToddSenior Vice President, Strategy and Business DevelopmentLast filed 11 May 2026 | |
Owners and trading
Largest institutional holders
Each fund group's share of Odyssey Therapeutics. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $20.3 million in 4 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 11 May 2026Buy | Nan (ln) LiDirector | $20M |
| 11 May 2026Buy | Shelley ChuDirector | $200K |
| 8 May 2026Buy | Jeffrey M. LeidenDirector | $100K |
| 8 May 2026Buy | Jason HaasChief Financial Officer | $20K |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no director or officer changes, WARN notices or large insider sales in the last two years.